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Abstract: This article explores the practice of gamete donation in the U.S. having in mind 
the larger question of what do we as a society owe children born as a result (donor-conceived 
children). Do recipient-parents have a duty to tell their donor-conceived child about his/her 
genetic origins? Should the identity of the donor be disclosed or remain anonymous? Does 
the child have a right to know her conception story and to receive information, including 
identifying information, about the donor? Furthermore, if a donor-conceived child has a 
right to know, who has the duty to tell her/him about it? The Article underscores the 
ethical, legal and social dilemmas that arise, comparing and contrasting with international 
developments in this arena. It highlights the market-based and more specific medical 
justifications for regulating this field, explores the emerging so-called right of the child to 
know his/her genetic origins (“the right to know”), and considers the challenges such a 
right evokes to existing legal culture and principles of medical ethics in the U.S. as well as 
other broader societal implications of such a right. 
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1. Introduction 
The practice of gamete donation has received growing attention in the past two decades. As an 
increasing number of individuals and couples resort and have resorted to gamete donation [1,2], and 
the number of donor-conceived children born as a result are reaching maturity, many are grappling 
with the question as to how to address the dilemmas that arise [3–8]. Do recipient-parents have a duty 
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to tell their donor-conceived child about his/her genetic origins? Should the identity of the donor be 
disclosed or remain anonymous? Does the child have a right to know her conception story and to 
receive information, including identifying information, about the donor? Furthermore, if a donor-conceived 
child has a right to know, who has the duty to tell her about it? 
In response to such questions, most legislatures in the Western world have taken steps to regulate 
the field [9–16]. Beyond informed consent of gamete donors and recipient parents, they have set 
limitations on the potential donors, the number of recipient families, the price for gametes, and the 
recording of the donor’s information [17]. An increasing number of countries have further reversed the 
long-held policy of gamete donors’ anonymity, collecting gamete donors’ identifying information and 
requiring their consent to be contacted in the future by any resulting donor-conceived child  
(see Section 3). 
In contrast, the market for assisted reproductive technologies in the U.S., including gamete donation, 
is barely regulated. There is no comprehensive law relating to assisted reproductive technologies, and the 
U.S. Food and Drug Administration (FDA) included gamete donations under its eligibility regulations 
for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (2007) [18]. These 
regulations require a review of “relevant medical records” and impose screening of donated gametes 
for predominantly communicable and infectious diseases (e.g., HIV, Hepatitis C), including six months 
quarantine and retesting before use of anonymous donations. Similarly, the American Society of 
Reproductive Medicine can only recommend that donors’ information is recorded and preserved. The 
regulation of private fertility clinics and gamete banks by individual states is also often lacking, and 
among those that have crafted regulations—there is great variation as to the collection, preservation, 
and release of donors’ information [5,19]. Given this stark difference between the U.S. and other 
developed, Western countries and their regulations of gamete donation, it is important to consider the 
justifications for this emerging international trend and its relevance to the U.S., as well as what 
implications such a change would entail for current principles of medical ethics. 
This paper aims to explore this issue, having in mind the larger question of what we, as a society, 
owe children born as a result of ART, especially from gamete donation. It endeavors to underscore the 
arising ethical, legal, and social dilemmas, rather than provide a comprehensive legal framework, 
which is beyond the scope of this article. Section 2 considers the context of gamete donation in the 
U.S. and highlights the medical justifications for regulating the field. Whether these justifications 
are—or should be—further translated into the emerging so-called right of the child to know his/her 
genetic origins (“the right to know”) is explored in Section 3. In addition, I present three main 
challenges such a right presents to legal framework and existing principles of medical ethics in the 
U.S. In Section 4, I consider two broader implications of the right to know. Finally, in Section 5, I 
make a few recommendations and draw some conclusions. 
2. Gamete Donation in Context: The U.S. 
Current calls to revise—or to more strictly regulate—the current market in the U.S. have to be 
considered in light of the tremendous medical, societal, and legal shifts that have occurred in the past 
few decades with regard to gamete donation. These include the number of parents who resort to 
gamete donation, and more importantly, the millions of children (worldwide) that have been born as a 
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result [1]; the increased societal acceptance of the procedure, which paved the way to its legalization, 
especially the regulation of the status of donor-conceived children and the recipient parents as a family 
unit [20–23]; and the development of medical guidelines that not only recognize infertility as a medical 
condition that can (and in many national healthcare systems, when requested, also should) be treated, 
but also that require service providers to follow certain standards such as transparent recruitment of 
donors [7], screening of gametes for various medical (especially infectious) diseases, and the securing 
of donors’ and recipient parents’ informed consent [18]. 
Of course, not all countries allow gamete donation, and the exact procedures for carrying out the 
practice vary significantly across countries [24–26], Indeed, as in other contexts of assisted reproductive 
technologies (e.g., surrogacy), laws and policies about gamete donation reflect many moral, legal, and 
cultural facets and countries strike a different balance between donors and recipient parents’ privacy 
interests and reproductive freedom and the child’s rights and best interests. However, even among 
those countries that allow gamete donation (of at least sperm), the U.S. market is unique. First, gamete 
donation in the U.S., as all other assisted reproductive technologies, is an outright, and undoubtedly 
thriving, commercial activity. It generates billions of dollars per year [27], donors’ recruitment is often 
made in public spaces (e.g., campuses, and increasingly, online), and uniquely to the U.S., donors, 
especially egg donors, are well compensated for their gametes [28,29] 1. In the absence of a centralized 
system to record gamete donations, donors may also donate multiple times and in various clinics,  
thus further increasing their profit from the donation. Second, and related, the “Wild Wild West” in the 
U.S. [30] 2  serves as a fertile ground for the creation of many thousands of (traditional and 
nontraditional [1]) families that would not have otherwise existed. In addition to American individuals 
and couples (both heterosexual and same-sex) who access assisted reproductive technologies, 
including gamete donation, the U.S. serves as a leading actor in the international reproductive tourism 
market [28]. Indeed, the estimate of donor-conceived children who are born in the U.S. each year is 
30,000–60,000 children from sperm donation [1] and over 8000 from egg donation [31]. 
Notwithstanding the moral condemnation some may raise for this business, this approach fits the U.S. 
creeds. As I elaborate in Section 3, the U.S. does not endorse the formal recognition of children as 
subjects with rights as other Western nations and prioritizes the rights and interests of adults, 
especially parents, over those of children. As a society that is highly invested in (adults’) freedoms—
reproductive freedom, privacy rights, and free market are especially relevant—many in the U.S. 
believe that the present system is satisfactory. 
Nonetheless, I suggest that these arguments can stand only as long as the interests of donor-conceived 
children are neglected. Certainly, it is highly controversial to talk about donor-conceived children as 
patients at the time of gamete donation or conception and even after implantation in the womb. The 
U.S. has long been split on the moral and legal status of such entities, as can be discerned from the 
                                                 
1  In the U.S., the payment peaks at $50,000 for egg donors and at $2950 for sperm donor (per cycle) [28]. For 
comparison, in the UK, Israel, and France, for instance, gamete donation has to be altruistic; financial compensation of 
gamete donors is limited to expenses and inconveniences directly associated with the donation. 
2  Dr. George Annas coined the notion of Wild West in medicine, which has been subsequently extensively used by others 
in an array of areas, including reproductive technologies (see [30]). Here, the notion of Wild Wild West followed 
Rosas’s title [19]. 
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ongoing debate about abortion. However, donor-conceived children are clearly the end goal of the 
process, and implications related to their circumstances of conception are likely to emerge after birth, 
when the child certainly has moral and legal status in society. Consideration of the interests of  
donor-conceived children is thus crucial for an informed discussion. 
In particular, an interest in accessing information about the donor may be especially relevant when 
donor-conceived children show medical symptoms, which may be the result of a genetic condition that 
the child inherited from the donor [3,4]. Although the genetic cause is not yet confirmed at this point, 
retrieving the donor’s information in such instances would arguably allow for quicker diagnosis, 
treatment, and adoption of preventative measures [4]. The sense of medical urgency arises also with 
asymptomatic children. In this regard, donors’ information may enable taking preventative measures,  
if needed (and possible), avoiding (future) consanguineous relationships between donor-conceived 
siblings, which increase the risk of genetic disorders if the siblings procreate [32,33], and allowing 
recipient parents and the donor-conceived child to make more informed reproductive choices [4]. 
To be sure, these arguments are not as absolute as they may initially appear. Many genetic disorders 
are multi-genetic and multi-factorial; they involve complex groups of genes not yet identified, as well 
as yet-unknown gene-environment interactions and epigenetic processes that are extremely difficult to 
decode [34]. Other genetic disorders are de-novo: they present for the first time as a result of a 
mutation in a germ cell of the fertilized egg itself, and cannot be attributed to the genetic parents [19]. 
Moreover, advances in genetic testing, especially genomic testing (such as whole genome sequencing 
and whole exome sequencing), are likely (or hoped) to make family history more redundant. These 
technologies may confirm a diagnosis that is based on known genetic disorders, provide information of 
individuals’ proclivity for such genetic conditions, and reveal information about genetic relatedness 
and carrier status without the knowledge of a family history. In the U.S., these technologies may 
further be more accessible to recipient parents and donor-conceived children than elsewhere because of 
the thriving market of direct-to-consumer genetic testing companies, which may test for ancestry and 
increasingly, for health conditions [35]. As a result of this market, not only have the costs of genetic 
testing have plummeted, but given that these companies rarely posit limitations on the age of their 
consumers [36], recipient parents and donor-conceived children may use their services. While 
Europeans may not view this market favorably [37], American primary care providers and the public 
are increasingly aware and supportive of these services [38]. Finally, and importantly, as Robert Klitzman 
points out: genetic diagnosis also does not mean that an effective treatment is available (so-called 
“diagnostic misconception”) [39]. Thus, regardless of whether genetic testing is provided in medical or 
commercial settings, the practical usefulness of having a genetic diagnosis may be questioned as well. 
Nonetheless, the rationales for regulating the market of gamete donation in the U.S. are grounded in 
both general and more specific deficits that arise in this market. In general, regulations of economic 
activities in the U.S. take place predominantly to protect weak consumers from strong service providers, 
including through addressing the problem of asymmetric information that these actors have [40]. In the 
market for gamete donation, the imbalance of information is clear: donors and clinics may hold 
significantly more information than the recipient parents, who are ultimately forced to accept the lack 
of information if they want to proceed with the gamete donation. The considerable vulnerability of 
prospective parents in accessing reproductive technologies, which beyond information includes 
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financial and psychological costs [1,41], should not be ignored 3. Furthermore, although both donors 
and recipient parents are the initial consumers, the goal of creating a child who is clearly impacted by 
this market necessitates that we view the donor-conceived children as “consumers in trust”. Conceptualized 
as such, the stronger players, especially fertility clinics and parents, should be required and are intuitively 
entrusted with the responsibility to behave in ways that will protect the rights and interests of  
donor-conceived children so they can exercise them in the future. 
The medical practice in the U.S. further gives rise to two other limitations that merit the regulation 
of this market. The first is the insufficient knowledge of genetics and genetic disorders among 
physicians. Studies consistently show that healthcare professionals, especially primary healthcare 
providers, including pediatricians and pediatric specialists, as well as fertility clinics are often lacking 
genomic literacy, and that they are unaware and untrained to make appropriate diagnoses of genetic 
diseases, especially rare ones [39,42–44]. In addition, when genetic testing is performed, healthcare 
professionals often express lack of confidence in interpreting the results and discussing genetic 
information with families [45]. The ability of front-line healthcare professionals to deliver health and 
genetic services to donor-conceived children is thus significantly curtailed. 
The privatized healthcare system further exacerbates this problem. Although this system builds on 
referrals to specialists, who could arguably provide better genetic services, the reality is that the 
number of genetic counselors is insufficient to respond to the demand [45,46]. For instance, a survey 
of pediatricians in Alabama found that 24% were unable to obtain genetic consultations for their 
patients, 67% said that face-to-face genetics evaluation was difficult or impossible, and 58% reported 
that even a remote genetics evaluation would be difficult or impossible [42]. The privatized healthcare 
system in the U.S. further raises a challenge of affordability. Unlike other Western countries where 
genetic testing is subsidized through the national healthcare services, insurance companies in the U.S. 
may, and commonly refuse to cover the costs [39] 4. Further worse, this practical obstacle creates a 
conceptual barrier that is hard for patients to cross. Min-Jye Chen et al., e.g., found that although 
pediatricians in the U.S. appreciate the value of genetic assessment, they may not order genetic testing 
or refer to a geneticist because of their concerns about the associated costs [47]. Thus, the donor-conceived 
child is the one to pay the price for this limitation: the time for a diagnosis and appropriate treatment 
are unnecessarily delayed. Clearly, the interests of these children are important. 
Second, the lack of regulations rewards the wrong (and stronger) actors in this market, to the 
detriment of donor-conceived children. Because of the U.S. privatized and often unaffordable 
healthcare system, recipient parents may find a genetic diagnosis useful in so much as it would enable 
them to sue the clinics for negligence to recover the mounting health-related costs. This is not to 
suggest that fertility clinics are necessarily liable for a donor-conceived child born with a genetic 
disorder or to promote such a claim (see Section 4). Rather, it is to emphasize that the child’s medical 
                                                 
3  I thank anonymous reviewer 2 for highlighting this point. 
4  The Patient Protection and Affordable Care Act of 2010 (known as “Obamacare”) does not change the previous  
decision-making process of insurance companies. Whether these insurance companies approve or reject the need for 
genetic testing depends on their judgment (correct or not) as to whether the procedure is medically required. Patient 
Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010) (codified as amended in scattered 
sections of 21, 25, 26, 29, and 42 U.S.C.). 
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needs should supersede the financial interests of fertility clinics, and that the regulations of the latter 
would increase the diligence in which fertility clinics select gamete donors and are able to follow up 
with donors when such a medical diagnosis arises. 
Indeed, in the lack of mandatory regulations, fertility clinics can neglect to follow up on medical 
information the donor provided, refuse to provide such information when requested by recipient  
families [48,49], or destroy the donors’ file altogether. Furthermore, fertility clinics may and often 
continue to use the gametes also throughout the period in which symptomatic donor-conceived children 
are being under medical investigation. Once again, this practice is especially problematic in the U.S. as 
no limitation on the number of recipient families that can receive donation from the same donor is set. 
Thus, for instance, in one reported case, the sperm of a donor with a genetic heart disease was used 
with at least thirteen families and produced twenty-two donor-conceived children, eight of which were 
diagnosed with the same genetic disorder (two died) [50]. In another reported case, gametes from one 
single donor was used to conceive forty-three children, five of which inherited the donor’s neurological 
disorder [44]. Put differently, the primary beneficiaries of the regulation-free market in the U.S. are 
gamete donors and fertility clinics who are in the business of making money, rather than the  
donor-conceived children who are—or are at risk for being in the future—in medical need. Thus, 
regulating this market is justified to prevent donor-conceived children who experience health symptoms 
from falling through the cracks and to prevent further use of gametes diagnosed with genetic disorders. 
3. The “Childs’s Right to Know”: Challenges in the U.S. 
Another emerging justification for the regulation of the market for assisted reproductive 
technologies in the U.S. is the suggestion that donor-conceived children have (or should have) a right 
to know about their genetic origin. Proponents of disclosure such as Lucy Frith, Vardit Ravitski, and 
Naomi Cahn, suggest that this “right to know” should be recognized as an inherent and universal right, 
including a right to know about one’s circumstances of conception, and a right to know information 
including identifying information about the donor [2,4,6]. Subsequently, although most countries in the 
world still uphold the policy of donor anonymity, there has been a visible international trend to reverse 
it. European, especially Scandinavian, countries as well as New Zealand and Victoria, Australia,  
have taken the lead, enacting laws that require gamete donors to provide both their medical and 
identifying information and to a-priori consent to be contacted by any resulting donor-conceived child 
in the future [9–13,51]. Victoria, Australia, further requires that an addendum is attached to the birth 
certificate of donor-conceived children, informing them about the donation and the availability of 
information about the donor [13,52]. A similar proposition in the UK failed [53]. 
In the U.S., recognition of such a right to know raises legal and ethical difficulties. Among the 
hallmarks of American society are the values of (adults’) reproductive freedom (in this case, of the 
recipient parents) and privacy rights of both the donors and the recipient parents. Moreover, the 
concept of familial privacy is strongly endorsed. Parents generally have a broad prerogative as to how 
to raise their children and to make decisions on their behalf, including in critical issues such as medical 
treatment. Although these concepts exist elsewhere, they are entrenched in the American psyche of 
individualism and self-proficiency—commonly contrasted to the European philosophy of state 
welfare/socialism—and have significant implications for children [54]. Indeed, the U.S. legal system 
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makes only little room for children’s rights. Unlike other Western counterparts that explicitly endorse 
children’s rights in their supreme legal framework [55,56], the U.S. neither ratified the United Nations 
Convention on the Rights of the Child [57] nor includes any mention of children as subjects of rights 
in its Constitution. Children’s rights are mostly based on judicial interpretive processes, which evolved 
primarily in areas where there are strong societal interests rather than (or, not exclusively) because 
minors’ interests (e.g., abortion) [56,58]. Conversely, it is well-accepted that parental prerogative is not 
unlimited, and courts generally support intervening on parental rights when the child’s physical health 
or safety is in serious danger [59]. The question is thus whether in the context of donor-conceived 
children such serious welfare-related harms exist and justify overriding parental prerogative. 
In this regard, disclosure proponents commonly raise three types of potential harm to the  
donor-conceived child, in addition to the medical harm already discussed. The first is familial harm, 
which focuses on the importance of the value of truthfulness. It suggests that family secrets create 
ongoing tension, taint the familial communication, and negatively impact the family relations [60]. The 
second is identity harm. As Vardit Ravitski, e.g., suggests, one’s genetic information is tied with one’s 
identity formation [4]. Analogizing gamete donation to adoption, this harm argument suggests that 
donor-conceived children can experience poor self-perception and identity crisis [6,61]; some have 
suggested that this amounts to so-called “genealogical bewilderment” [33]. Finally, the third focuses 
on kinship. It suggests that genetics intrinsically makes U.S. feel emotionally close to our kin, and that 
to prevent “genetic alienation”, a donor-conceived child has a right to materialize this intrinsic 
connection through the provision of information and especially the ability to develop a relationship 
with the genetic parent [4,7]. 
The remainder of this article considers whether these harms justify overriding parental prerogative. 
The emphasis is on the U.S. context (rather than general or abstract consideration), focusing on three 
issues. The first concerns the weight granted to genetics. It is, of course, undeniable that genetics 
impacts issues such as appearance, temperament and propensity to develop certain health conditions. 
However, the argument, as advanced by disclosure proponents, goes deeper. It suggests that genetics is 
a prime—even the prime—factor that determines who one is, and thus justifies trumping the interests 
of others. Indeed, a right to know and the subsequent harm of not knowing emerge only if genetics is 
upheld as indispensible, and a prerequisite, to one’s personhood. Such a genetic-essentialist 
understanding of one’s self and identity is misleading, however. It overstates individual’s genetic make 
up and insinuates that one’s “authentic” identity and personality traits are grounded merely in one’s 
genes—although scientific knowledge has proven this wrong [62]. It also downplays other factors that 
are critical in the development of identity, especially the role of society and the environment. Indeed, 
perhaps the biggest message of literature on disability, genetics, and identity is how multifaceted the 
process of identity formation is, and how societal exclusion is influential in this process [63]. 
Further significant is how culturally constructed is the notion of the genetic tie and its importance 
more generally. One example 5 is the case of egg donation in which the recipient mother carries the 
pregnancy. In such scenarios, both the genetic and gestational mothers have a biological role in the 
resulting child. However, while emerging studies in epigenetics show that the gestational environment 
influences how the fetus’s genes are later expressed [64], Susan Golombok et al’s study of children 
                                                 
5  I thank anonymous reviewer 1 for a comment that instigated this example. 
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born through reproductive technologies found that, at age 7, surrogacy children show higher levels of 
adjustment difficulties than children resulting from egg or sperm donation [65]. Determining whether, 
for the child, it is really the genetic rather than gestational tie that is critical, or whose maternal contribution 
“counts more” for the child’s identity depend on one’s construction of motherhood and is thus 
impossible. Another example is Orthodox Judaism construction of fatherhood. Under this religious 
stream, non-Jewish men who have a (genetic) child with a Jewish woman are not held as having any 
paternal relatedness with the child [66]. There is subsequently a denial of the need to know, and from 
the perspective of members belonging to such communities, any arguable harm by not knowing is odd. 
This is not to say that the position of parents and other figures belonging to such religious 
communities should necessarily prevail. For donor-conceived children who are raised in such religious 
communities and who adopt a similar worldview, non-disclosure of one’s genetics origins may be the 
appropriate decision. However, the views of recipient parents and donor-conceived children (especially 
mature ones) might not be in sync. Because children are separate human beings from their parents, it is 
impossible to unquestionably assume that they will follow the parent(s)’ religion and ideology. 
Children may opt out of the religious community and, as studies show, may develop their own identity, 
separate from their parents [67]. Regardless of parental preferences and religious ideology, then, 
donor-conceived children may indeed be curious about their genetic origins. In fact, the call for a 
child’s right to know has emerged seemingly because of such instances: when disclosure of the child’s 
circumstances of conception occurred in traumatic circumstances, such as during parental divorce 
proceedings or from a third party, and the donor-conceived child subsequently developed an identity 
crisis akin to that documented for adopted children [68]. For such instances, an organized registry of 
gamete donors would enable the child to access information about the donor—even if not necessarily 
identifying information—if she finds it fit. Put differently, further regulations of gamete donation in 
the U.S. can provide the framework to protect the interests of donor-conceived children (and future 
adults) without classifying these as a right to know, which current American legal system and culture 
are likely to resist. 
A second issue to consider is the scope of the right to know and what such a right actually means. 
Obviously, one’s circumstances of conception are critical for the child’s right to know. Yet if knowing 
this includes a detailed description–from gamete donation, to parental use of medication, in-vitro 
fertilization (IVF) treatment 6, and so forth—it would altogether eschew parental privacy rights. It is 
further doubtful whether knowing about one’s circumstances of conception would be enough. 
Testimonies of some donor-conceived children suggest that knowing about their circumstances of 
conception but having no access to information about the donor produced anxiety and self-doubts about 
who they are [61,68]. While meeting with half-siblings through on-line listserves (such as the Donor 
Sibling Registry [69]) may mediate some of the frustration, the relief is only partial, suggesting that 
more information is needed. Yet the concept of a right to know does not clarify what else, besides 
circumstances of conception, one has a right to know. 
Surely, it would include the donor’s medical history as collected by the fertility clinic that provided 
the service (see discussion above). But as the study of the human genome develops, one may equally 
                                                 
6  In in-vitro fertilization the woman’s egg is fertilised by sperm outside of the body, in a Petri dish, and then implanted in 
the womb. 
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argue that the medical file should include donor’s genomic data (including, e.g., information about 
behavioral traits), or that the donor be tested for genetic disorders whenever appropriate technologies 
develop to include this information in the medical file. However, genetics information is often 
unknown to the donor him/herself—even if only out of fear from discrimination [39]. Although the 
Genetic Information Nondiscrimination Act of 2008 (GINA) [70] unified the ban of genetic-based 
discrimination in employment and health insurance across U.S. states, the Act has some important 
limitations [71]. Moreover, studies suggest that public fear from genetic-based discrimination is  
high [72,73]. Recent recommendations from the American College of Medical Genetics and Genomics 
about clinicians’ duty to report incidental findings of genetic mutations [74] further complicate the 
issue. While the ACMG has listed fifty-seven genetic mutations that are clinically actionable (i.e., 
when medical intervention exists), donors may practically be forced to receive information they may 
not want to know. In effect, then, the privacy rights of donors, and their right not to know, would be 
subjected to the child’s right to know. 
Even if access to a donor’s genetic information may be justified when donor-conceived children 
experience various medical symptoms, the implications of providing such information, which may go 
beyond the recommended list of the ACMG, also to donor-conceived children who are asymptomatic, 
merits caution. As Klitzman’s extensive study of adults who underwent genetic testing reveals, whether 
knowing about one’s genetic composition is helpful and desirable depends on a myriad of factors, 
including personality, family and social circumstances, the availability of treatment, and others [39]. 
How such information will be disclosed to asymptomatic donor-conceived children is a further reason 
for concern. Given online listserves for recipient parents and sibling donor-conceived children, it is 
crucial to ensure that information about potential genetic disorders is not merely posted on the web but 
provided by experts who can explain the implication thereof and provide the needed support. 
This challenge is more pronounced in the U.S. given, on the one hand, the privatized healthcare  
system with its limitations, as described above, and on the other hand, the burgeoning market of  
direct-to-consumer genetic testing companies. In particular, studies suggest that genetic testing of 
children through the latter is increasingly viewed as a parental prerogative [75], and that some of the 
leading companies (e.g., 23andMe) in fact also target young consumers (ages > 13) when designing 
and marketing their genetic services [76]. These companies further increasingly offer an array of social 
networking opportunities and encourage consumers to share their genetic data through these platforms [71]. 
Notwithstanding the FDA’s 2013 suspension of marketing of health-related genetic testing by 
23andMe on the ground of lack of clearance for scientific accuracy of testing [77], it recently granted 
the company the first permit to provide a genetic carrier test for Bloom syndrome [35], and the 
expectation is that additional permits will be granted over time as technologies are more accurate. 
However, while these direct-to-consumer companies will be able to provide (especially in the future, 
as the tests are also offered at lower costs) an alternative to families who are uninsured or whose 
insurance companies denied the request for testing, these companies do not currently provide professional 
support to understand the genetic implications to consumers. The concern that donor-conceived children 
(especially adolescents) will use these private services to connect with genetic kin but end up learning 
unexpectedly about their proclivity for certain genetic conditions without being provided with medical 
and other supports in this disclosure is thus heightened. 
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Moreover, this possibility raises a concern that the child’s right not to know may be unintentionally 
violated. The right not to know, which is based on notions of individual autonomy and privacy, is well 
established in Western medical practice, especially in the context of genetic data [78]. However, given 
that these direct-to-consumer companies do not have a mechanism in place to ensure that consumers 
understand the implications of their consent [71], it is unclear, indeed, doubtful, that donor-conceived 
children who access these online services are well informed about the possibility that in searching for 
genetic kinship they may forfeit their right not to know about genetic proclivity for disorders. Once 
again, then, regulations of this market, including FDA oversight of direct-to-consumers genetic 
services and mandatory counseling, could alleviate the concern and protect the legitimate interests of 
donor-conceived children without classifying this as a child’s right to know that is unlikely to be 
endorsed in contemporary American legal culture. Such regulation will also be in line with U.S. 
requirement of informed consent and rationales for regulating economic markets (indeed, it is for these 
rationales that the ability of such direct-to-consumer companies to provide health-based services is 
currently significantly limited [79]), and thus easier for the American public to adopt. 
The conceptualization of access to donor’s medical and genetic information as a right is further 
problematic as it suggests that naturally-conceived children should also have a right to access their 
parents’ medical information [80]. After all, by definition, a right is an entitlement that all children 
should equally have. Yet no such right currently exists 7. Furthermore, given that medical issues, especially 
genetic conditions, are often not shared also with other members of the family [39], acknowledging 
such a right would create a revolution with regard to privacy in medicine which would be very difficult 
to implement. The challenge is, therefore, if and how to support donor-conceived children without 
simply replacing the privacy rights of both recipient parents and donors with however we conceptualize 
the right to know, and indeed, without unintentionally harming donor-conceived children by providing 
them information they might not want to know. 
A third dilemma with the right to know concerns the procedure for disclosure. If the child has a 
right to know, there should be a mechanism in place to facilitate the child’s knowledge of her/his 
circumstances of conception and access to donor information. As a society, there also needs to be a 
decision as to who has the duty to disclose the circumstances of conception and other data about the 
donor to the child. Of course, truthfulness is often regarded as an important virtue. It is a core principle 
in Western bioethics, where it is part of the doctrine of informed consent, and, as mentioned, children’s 
advocates suggest that it is paramount for healthy family-relations. There is therefore an expectation 
that parents will do “the right thing” for their child and disclose the story of conception. 
Most laws that regulated gamete donation and follow this idea (e.g., the Netherlands [10], the UK [11]), 
have adopted so-called “passive registries” [80]. Although these laws require that providers of reproductive 
services record some identifying information about the donor, the donor-conceived child is the one 
who is expected to initiate the release of information at maturity (usually assumed to be achieved at 
16–18 years old). The problem with such registries is that their usefulness is typically limited to 
nontraditional families (single parent or same-sex couples), where the use of gamete donation is 
naturally more obvious, or to other instances where the donor-conceived children already know and 
                                                 
7  See however Safer v. Estate of Pack (I), 291 N.J. Super. 619, 677 A.2d 1188 (App.Div.), certif. denied, 146 N.J. 568, 
683 A.2d 1163 (1996). 
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can initiate such disclosure proceedings. However, they are significantly less useful with heterosexual 
couples who resort to gamete donation. Indeed, studies show that the preponderance of donor-conceived 
children born to heterosexual couples do not know about their genetic origins [68]. Thus, if a  
donor-conceived child indeed has a right to know, there should be a system in place to ensure that the 
child is informed about his/her genetic origins. 
One such option is to obtain the prospective recipient parents’ commitment to disclosing the gamete 
donation to the child. As Adrianne Asch suggested, only once this condition is satisfied, parents will be 
“licensed” to proceed with the procedure and use donated gametes [8]. Although this may provide an 
initial solution, it is limited in that it does not include an enforcement mechanism. Studies in the UK, 
for instance, found that although recipient parents are encouraged to disclose the gamete donation to 
the child, only 30%–40% of heterosexual couples intend to do so [81,82]. Further, heterosexual recipient 
couples that pre-procedure express an intention to disclose the gamete donation to their child may not 
follow suit. Thus, an additional implementation procedure of the child’s right to know will be needed, 
that is, it will require that an “active registry” be adopted [80]. Under such a registry, gamete banks or 
another body would contact the donor-conceived child at the age of maturity. Another option would be 
an addendum to the child’s birth certificate, stipulating his/her circumstances of conception, as adopted 
in law in Victoria, Australia, and debated in the UK [13,52,53]. This would ensure that donor-conceived 
children indeed know and can request the donor’s information later on. 
However, the extent to which these regulations can and should be adopted in the U.S. requires 
consideration of three related issues. First, an active registry inherently assumes, as commonly also 
implied in the scholarly work, that truth-telling in the context of gamete donation and the subsequent 
policy of disclosure is an absolute good. In practice, however, truth-telling—including in the realm of 
medical ethics—is relative. For instance, as Ruth Macklin points out in her work on relativism in 
medical contexts, physicians may avoid saying the word “cancer” to a patient who is terrified of dying 
from the disease when she is diagnosed with a benign tumor, if full disclosure would lead to a  
crisis [83]. Similarly, there is no consensus whether physicians who during medical diagnosis and 
treatment of child incidentally discover that there is no biological relationship between the parent 
(usually, father) and child (so-called: “misattributed paternity”) ought to disclose this information (and 
to whom) [80,84]. In some cases, the healthcare providers decided to disclose this information to the 
family members involved; but in others, the medical team found it to be irrelevant [85–87]. 
Comparable “relativist” justifications may exist in the context of gamete donation. Among Orthodox 
Jewish and Muslim communities, for instance, the pressure to procreate may be so high that a husband 
may be religiously or culturally obliged to divorce his wife on the basis of infertility [20,88]. 
Concurrently, the use of gamete donation may be viewed as prohibited adultery with significant 
ramifications on the social and religious status of both recipient parents and the donor-conceived child, 
who may then be ostracized from the community altogether [20,55,66,88,89]. While discussing the 
option of disclosure with such recipient parents who nonetheless decide to procreate by using gamete 
donation would be appropriate, insisting on truth-telling, especially when there is no medical necessity, 
may have unnecessarily high costs for both recipient parents and the child. Such insistence will also 
contradict the U.S. approach, which prides itself as being a “melting pot society” and requires respect 
of religious and cultural diversity in private lives. 
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Such interference in parental disclosure decisions is especially troubling, given that as a practical 
matter, it is questionable whether not knowing indeed harms the child at all. As mentioned, there are 
some testimonies of donor-conceived children who expressed frustration and identity doubts because, 
although they know about their conception story, they do not have access to information about the 
donor. The frustration and agony of such children should be taken seriously by all involved in the 
process, and the regulations of gamete donation as suggested may facilitate greater openness in the 
future. However, this is by no means universal. Studies with children born as a result of sperm donation, 
and raised by families with various structures show mixed results. Interestingly, diversity in views and 
preferences exists also among donor-conceived children who are raised together in one family [90]. 
Some prefer anonymity; others are satisfied with non-identifying information; and yet still others want 
to know identifying information about the donors [90–92]. Moreover, to my knowledge, there are no 
studies of the relative occurrence of identity crisis among the general population of donor-conceived 
children, including especially the millions who do not know about their genetic origin, nor about 
whether their identity crises are any different than what other children experience as they go through 
their adolescence years. On the contrary: as Golombok has found in her decades long research of 
children conceived by sperm and egg donations, including some who do not know about their 
conception story, the quality of family relationships and children’s socio-emotional adjustment and 
psychological development to be within the normal range [93–95]. The researchers subsequently 
concluded that these family relationships and subsequent child development “do not represent a cause 
for concern” [94]. Thus, there is a concern that by prioritizing truth-telling as an absolute good, we are 
sanctioning an intrusion into family relations and children who are otherwise flourishing. 
A second issue regarding disclosure and active registries concerns the role that physicians should 
have in upholding the child’s right to know. That is, the conceptualization of data about one’s genetic 
origins and disclosure of donors’ data as a right suggests that there is—or should be—a parallel 
societal obligation, including physicians’ duty, to uphold the child’s right to their best of their abilities. 
Indeed, in countries that adopted a gamete donation disclosure policy and active registry, there is a 
national/state level registry, and physicians are required to notify regarding the patients and successful 
births [9–13,51]. Such notification by physicians is possible on a practical level also because fertility 
services, including gamete donation, are provided as part of the national healthcare system. Neither of 
these conditions exists in the U.S., however. Physicians in the U.S. are not normally required to disclose 
identifying information about patients to third parties, including under the Center for Disease Control’s 
National ART Surveillance System [96] 8. While exceptions exist (for instance, reporting on lethal 
infectious diseases [97] or when a patient may be harmful to others [98]), it will be hard to expand it to 
individuals and couples who are going through a fertility treatment, even though they do not have 
medical conditions which are risky to others and regardless of their consent. Indeed, such physician’s 
notification will require revamping confidentiality laws in medicine as currently exist in the U.S. 
Such surveillance is also significantly more complicated in the U.S. because of the fragmentation of 
the healthcare system. Given the privatized healthcare system, infertility services and treatment during 
                                                 
8  Fertility clinics are required to provide information on pregnancy outcome to the Center for Disease Control as part of 
the National ART Surveillance System; however, patients’ information such as name and address is not reported and 
remains confidential. 
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pregnancy are commonly carried out by different physicians, and often, in different states. One 
possible way to overcome this fragmentation is to require that all newborns be tested to ensure that 
they have genetic compatibility with their presumed parents, and that the results of these tests will be 
recorded on the birth certificate. This option is clearly highly intrusive in family life, and given the 
estimates that ten percent of children born in the U.S. to heterosexual couples are unknowingly raised 
by non-biological fathers [99], it is also unlikely to pass American standards of privacy. 
Finally, the third consideration regarding the disclosure of donor’s identifying information and 
active registry concerns the impact it will have on the overall market. Given that many gamete donors 
(especially sperm donors) are uninterested in the resulting child [68] 9, and that they often donate 
mostly for financial reasons [100], all countries that reversed the policy of anonymity encountered two 
challenges: a significant drop and subsequent shortage in gamete donation, especially for ethnic 
minority groups [29,101,102], and simultaneously, an increase in fertility tourism where those who can 
afford it travel to the U.S. and to other destinations which are less regulated and where donors’ 
anonymity is upheld [28]. Also, the demographic characteristics of gamete donors have changed. 
Studies suggest that sperm donors tend to be older and often married, with some also reporting higher 
rates of men with mild psychopathology and alcohol abuse [68]. Such characteristics are clearly less 
favorable for a donor-conceived child. Thus, regulations of gamete donation in the U.S. should take 
into account how to balance the various interests of donors, recipient parents and donor-conceived 
children, and, possibly, also the market as a whole. 
Revisiting the process of donors and recipient-parents’ informed consent may facilitate this goal. 
First, this process could include encouragement of gamete donors to leave some personal information 
in their file at the time of donation (similar to adoption [2]), and service providers may further create a 
mechanism that allows donors to provide such information later on. In this way, donors who initially 
opted for anonymous donation but changed their minds over time (which may happen, especially as 
donor-conceived families become even more accepted) will be able to revisit their decision. Second, 
the type of information provided to stakeholders should be reconsidered. In addition to the conventional 
requirements of data about the medical procedure, risk, and benefits, service providers may include 
research about donor-conceived children and references to other sources (e.g., the Donor Sibling 
Registry’s website) that would better inform these stakeholders about the needs and interests of (some) 
of the resulting children. An opportunity to meet or talk with recipient families who can share their 
experiences could also be offered. Although not currently offered elsewhere (to my knowledge), such a 
mechanism to promote informed decisions exists in other medical contexts. For instance, the Federal 
government and a few states in the U.S. have enacted laws requiring that prospective parents who 
undergo prenatal genetic testing and find that their fetus has Down Syndrome are offered to meet with 
families with and organizations providing services to such children before deciding whether to abort or 
continue the pregnancy [103–105]. Although these laws raised some concerns (predominantly because 
they are viewed as a disguise for pro-life/anti-abortion philosophy) [106], the value of increased 
information is uncontested [107]. A similar opportunity could thus be extended to gamete donors and 
recipient-parents. Given that some recipient parents may desire more information about the donor 
(either for themselves or because of their child’s quest) [17] or be unaware of the possible ramifications 
                                                 
9  Women have expressed greater interest in future offspring. 
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of lack of such information, such a pro-information mechanism may further empower them as consumers 
to demand a more transparent process, reduce the costs of purchasing gametes from non-anonymous 
donors (which are currently higher than gametes from anonymous donors [2]), and mobilize the market 
in a different direction. 
4. Broader Social Implications 
In addition to the challenges to medical ethics that arise in light of the child’s right to know, the 
recognition of such a right might also have broader social implications which merit consideration. 
The first is that a right to access donor’s medical and genetic information may give the wrong 
impression—indeed, illusion!—to recipient parents (and to society more generally) that they are 
guaranteed to have disability-free children. A language of rights suggests that there is a corresponding 
duty on parents and, by extension, on gamete donors and fertility clinics, to know about and to avoid 
passing along genetic disorders. Certainly, this is not a new debate [80,108–111]. It arose with the 
genetic revolution and gave rise to the possibility of so-called “wrongfully disabled” cases, where 
children sue their parents for being born with a genetic disorder that parents could have theoretically 
prevented through the use of technology. Courts thus far have refrained from accepting such  
cases [48,112]. However, if access to parental medical and genetic information is re-conceptualized as 
a right, it may spur new interest in such “wrongfully disabled” suits. This will require judicial resolution 
of questions about whether there is or should be a parental duty to prevent harmful conditions in their 
child, including a predisposition to genetic disorder; what sort of disabilities give rise to such a 
parental duty; and by extension, what are the reasonable expectations from gamete donors and fertility 
clinics in testing for genetic disorders. However, given that a “positive genetic test” rarely provides 
information about the actual likelihood for the disorder to occur, its severity, and the expected time for 
onset of the associated disorder [34,113], the answers to these questions are not obvious. 
Further, given that there is no study showing that the rate of donor-conceived children with 
disabilities is higher than what it is in the general population and that disability is a natural 
phenomenon, the implied message about disability-free children as encapsulated in the right to know is 
concerning. As many persons with disabilities and their advocates have pointed out, such claims send 
the (wrong) message of lesser value in a life with disabilities [8,114,115]. It may further exacerbate 
societal stigma and discriminatory attitudes towards persons with disabilities. Indeed, while there is 
strong and consistent evidence that the “geneticization” of conditions such as psychiatric disorders 
increases stigma [116,117], it is often also the case that the genetic identification of such complex 
disorders is impossible at this point to achieve. 
Second, the implications of the right to know on the societal construction of the family should be 
considered. Theoretically, recognizing the right to know reflects well upon the reality of the new 
families. It acknowledges the donor’s contribution, which enabled the creation of these families, 
regardless of their exact structure. It is also tuned to studies showing that children’s sense of familial 
attachment often adjusts to their familial structure and that, for children, the most important thing is 
that they were planned and wanted all along [118–120]—qualities which are undisputable in the 
context of assisted reproductive technologies, gamete donation included. Thus, a right to know also 
sends an important message of acceptance of familial diversity in society, and should be promoted. 
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In the U.S., however, a right to know may serve as a double-edged sword vis-à-vis the legal and 
societal constructions of the family. Notwithstanding the recent landmark decision of the U.S. Supreme 
Court that legalized same-sex marriage across the states [121], social acceptance of family diversity is 
not automatic. In this regard, and even though it may not be intentional, the emphasis on one’s genetic 
origins may reinforce the traditional family comprised of a genetic father and a genetic mother as the 
ultimate family structure and undermine other non-traditional family structures of these donor-conceived 
children [122]. Conversely, a right to know intuitively moves towards a reality of a “multi-parents” 
family model [123,124]. Even if gamete donors do not currently have a say in the child’s rearing, a 
donor-conceived child who matures might chose to have some sort of a parental or other relationship 
with the donor, and donors might find that a relationship with their genetically-related children is 
nonetheless desirable [125]. However, this intuition immediately encounters the “two-parents-only 
model” which is prevalent—and paramount—in family law and culture in the U.S., which limits the 
number of the legally recognized parents—whether heterosexual or same-sex parents—to two [126–129]. 
While a legal overhaul of the two-parents model may not be needed, and in most likelihood, also 
undesirable to many donors and recipient parents, encouraging openness about alternative or more 
fluid parenthood structures is appropriate. Indeed, studies of the increased trend in adoption and 
surrogacy agreements to preserve some contact between the adoptive/surrogacy families (both parents 
and children) and the genetic and gestational parent(s) indicate that even little contact improves the 
overall positive experience of all involved [130,131]. Conversely, by recognizing a right to know 
without making appropriate adjustments in family laws and without creating the societal acceptance of 
such families, the dissonance between law, society and medicine in the construction of the family may 
be exacerbated. Once again, the prime victims are the resulting children. 
5. Conclusions 
There is no question that scientific developments in reproduction have changed the landscape of the 
family. Gamete donation is no exception, and it requires that attention be given to the medical, familial 
and social implications thereof, including the resulting children. 
Medical needs of donor-conceived children, coupled with general rationales for regulating economic 
activities and more specific deficits in medical practice in the U.S., provide strong justifications for the 
regulation of this market. This is especially true given the privatized and fragmented healthcare system 
in this country. Simply stated, the existing system considers the interests of all but the donor-conceived 
children, who are the only ones who have no say as to whether to be born. Regulations of this market 
may also enable addressing other challenges, and balancing the interests of stakeholders, that  
are unique to the U.S. system. These include respect for multicultural societies while upholding  
donor-conceived children who may develop religious and cultural perspectives that are different than 
those of their parents’, protecting their interests as “consumers in trust”, and safeguarding them given 
the rise of direct-to-consumer genetic testing market and its tempting but possibly harmful social 
networking options. 
A national, comprehensive, legislation relating to gamete donation—akin to that in other developed 
countries—is likely unfeasible in the U.S. at this this point. However, there is room for increased 
regulations, which would be in sync with the U.S. creeds. Without intending to be exhaustive, some 
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suggestions to this affect include increasing genetic and genomic literacy among physicians, especially 
Ob-Gyn, pediatricians, and service providers in general. More oversight by Federal agencies, including 
the FDA and the Center for Disease Control about the type and extent of donors’ data that is collected 
(and preserved) and the possibility of follow up with donors and later update of donors’ files. In this 
way, regardless of whether recipient parents and donor-conceived children are aligned in their quest 
for donors’ information, some recourse for donor-conceived children who want access to donors’ 
information will exist. Additionally, recent studies found that non-anonymous gamete donors express a 
need for counseling also a few years post-donation [132], and ensuring access to such services will be 
important. However, as suggested earlier, it is also critical that mandatory genetic counseling is provided 
to recipient parents and mature donor-conceived children, especially those who are using online 
services and direct-to-consumers companies in search for genetic kinship. This will protect  
donor-conceived children from unknowingly forfeiting their right not to know about genetic conditions 
that may be traced back to the donor. Given the U.S. legal, political, and free-market market cultures, a 
fully centralized registry of gamete donors will be difficult to achieve. It may also lead to a major drop 
in supply—a backlash that powerful actors in the U.S. reproductive market, including prospective 
recipient parents, will certainly resist. However, pro-information laws and mechanisms to improve 
stakeholders’ informed consent process are entirely within the U.S. rationales for regulating markets  
and principles of medical ethics. Raising awareness about the possible needs of the resulting children 
could also empower prospective parents/consumers to demand greater transparency and reduce 
antagonism among donors. 
Whether there is a moral-translated-into-legal donor-conceived child’s right to know requires 
further consideration, and it is particularly complicated in the U.S. given its culture and legal 
framework pertaining to children’s rights. The moral backdrop of such a right is complicated, given 
existing religious and cultural pluralism in the U.S., and the legal and societal value of individualism, 
reproductive freedom, non-interference in family matters, and (adults’) privacy rights that in general, 
supersede children’s rights. A legal right is further fraught with an array of medical, practical, and 
social dilemmas as to what it actually means, how it can be implemented, and at what benefit—and 
cost. Whether truthfulness is an absolute good, how to balance between access to donor’s medical and 
genetic information and privacy in medicine of parents and donors, and what role physicians have—or 
should have—in upholding this emerging right to know all suggest that rethinking some fundamental 
principles of contemporary medical ethics in the U.S. is needed. The broader social implications of this 
right to know, especially the implied guarantee of disability-free children, the implications of geneticization 
on stigma and discrimination against persons with disabilities, and the societal construction of the 
family (along with the appropriate legal measures to support it) are too important not to consider. 
There is much room for further research is this field, not least by adding the perspectives of  
donor-conceived children across family structures and religious/cultural diversity including the voices 
of donor-conceived children who do not know their conception story. Fleshing out questions 
concerning disclosure of genetic information and diagnosis to donors and donor-conceived children 
should further be explored, along with the responsibility of fertility clinics in doing so. The debate 
surrounding disclosure of gamete donation raises too many interests, concerns, and duties to ignore.
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